Merger positions Supernus as a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, enhanced financial flexibility and a differentiated
Record total revenues of $226.8 million in the third quarter 2026, an 18% increase compared to same period last year.Combined revenues of the Company's four growth products increased to $192.2 million in the third
NEW YORK, Oct. 28, 2026 /PRNewswire/ -- Huron Consulting Group Inc. (NASD: HURN) will replace Supernus Pharmaceuticals Inc. (NASD: SUPN) in the S&P SmallCap 600 before the opening of trading on Tuesday, November 3,
The ‘Ms. Represented’ campaign expands its reach with professional snowboarder Chloe Kim, who shares her ADHD experience to help connect with a younger generation of women.More than 60% of U.S. women who reported ever
NEW YORK, Oct. 22, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600:
MSG Rangers Inc. (NYSE:MSGR) will be added to the S&P SmallCap 600 effective prior to
Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO Additionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by mid-year 2027
ROCKVILLE, Md., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Supernus Pharmaceuticals, Inc. (NASDAQGM:SUPN) to
ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous
Chloe Kim is partnering with Supernus to highlight the importance of recognizing ADHD in adults and help empower individuals to work with their doctors to develop a tailored treatment plan.While ADHD is often associated
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.The proposed transaction may contain terms that could limit superior competing offers.Shareholders are encouraged to
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Supernus Pharmaceuticals, Inc. (NASDAQGM:SUPN) to
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged
